Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

Stecklein, SR; Mart&#237;n, M; Bras&#243;-Maristany, F; Villacampa, G; &#193;lvarez, EL; Del Monte-Millan, M; Echavarr&#237;a, I; Yoder, R; Bueno-Mui&#241;o, C; Pathak, H; Garc&#237;a-Saenz, J&#193;; Cobo, S; G&#243;mez, HL; Par&#233;, L; Mar&#237;n-Aguilera, M; L&#243;pez-Tarruella, S; Jerez, Y; Cebollero, M; Bueno, O; Moreno, F; Massarrah, T; Herrero, B; Buckingham, W; Villagrasa, P; Godwin, AK; Salgado, R; Prat, A; Sharma, P

Author(s): Stecklein, SR; Martín, M; Brasó-Maristany, F; Villacampa, G; Álvarez, EL; Del Monte-Millan, M; Echavarría, I; Yoder, R; Bueno-Muiño, C; Pathak, H; García-Saenz, JÁ; Cobo, S; Gómez, HL; Paré, L; Marín-Aguilera, M; López-Tarruella, S; Jerez, Y; Cebollero, M; Bueno, O; Moreno, F; Massarrah, T; Herrero, B; Buckingham, W; Villagrasa, P; Godwin, AK; Salgado, R; Prat, A; Sharma, P;
Details: Publication Year 2026-02-01,Volume 118,Issue #2,Page 354-359
Journal Title: Journal of the National Cancer Institute
Publication Type: Research article
Abstract: Patients with triple-negative breast cancer (TNBC) who achieve pathologic complete response (pCR) to neoadjuvant systemic therapy have favorable survival, while those with residual disease have high recurrence risk. Stromal tumor infiltrating lymphocytes (sTILs) and TNBC-DX both predict pCR in TNBC. Whether these 2 biomarkers provide complementary information has not been tested. We evaluated sTILs and TNBC-DX in TNBC patients treated with docetaxel-carboplatin (TCb) on the MMJ-CAR-2014-01 study (NCT01560663) or TCb plus pembrolizumab (TCb+Pem) on the NeoPACT trial (NCT03639948). sTILs and TNBC-DX independently predicted pCR in patients treated with TCb+Pem. Patients with sTILs ≥ 30% and a TNBC-DX pCR-high genomic score achieved a pCR rate of 91.3% with TCb+Pem. An integrated classification incorporating sTILs and TNBC-DX identified approximately 40% of the NeoPACT cohort with a pCR rate exceeding 85%. The integrated classification was prognostic for event-free survival in patients treated with TCb+Pem. Integrating sTILs and TNBC-DX may facilitate chemoimmunotherapy escalation and de-escalation trials.
Publisher: Oxford University Press
Keywords: Humans; *Triple Negative Breast Neoplasms/drug; therapy/pathology/immunology/genetics/mortality; *Lymphocytes, Tumor-Infiltrating/immunology/pathology; Female; Prognosis; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Middle Aged; Carboplatin/administration & dosage; Docetaxel/administration & dosage; Antibodies, Monoclonal, Humanized/administration & dosage; *Biomarkers, Tumor; Neoadjuvant Therapy; Adult; Aged
Department(s): Laboratory Research
Publisher's Version: https://doi.org/10.1093/jnci/djaf162
Open Access at Publisher's Site: https://doi.org/10.1093/jnci/djaf162
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-08-08 07:40:24

Last Modified: 2026-03-02 05:02:25